[go: up one dir, main page]

TW200628158A - Promoting neochondrogenesis using kinase inhibitors - Google Patents

Promoting neochondrogenesis using kinase inhibitors

Info

Publication number
TW200628158A
TW200628158A TW094134143A TW94134143A TW200628158A TW 200628158 A TW200628158 A TW 200628158A TW 094134143 A TW094134143 A TW 094134143A TW 94134143 A TW94134143 A TW 94134143A TW 200628158 A TW200628158 A TW 200628158A
Authority
TW
Taiwan
Prior art keywords
neochondrogenesis
promoting
kinase inhibitors
compounds
methods
Prior art date
Application number
TW094134143A
Other languages
Chinese (zh)
Inventor
Vijaykumar Mahalingappa Baragi
David Wayne Brammer
Cynthia Lee Courtney
Brian Craig Korniski
Charles Alfred Lesch
Original Assignee
Warner Lambert Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=35447209&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=TW200628158(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Warner Lambert Co filed Critical Warner Lambert Co
Publication of TW200628158A publication Critical patent/TW200628158A/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/4985—Pyrazines or piperazines ortho- or peri-condensed with heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders

Landscapes

  • Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

This invention provides methods for utilizing compounds that inhibit cyclin-dependent kinase and tyrosine kinase enzymes in the promotion of neochondrogenesis and the enhancement, protection and repair of cartilage. In certain embodiments the invention relates to methods of using compounds of formula I: , and pharmaceutically acceptable salts thereof, to promote neochondrogenesis, wherein, R1, R2, R3, R4, R5, R6, A, B, D, and E have any of the values defined therefor in the specification.
TW094134143A 2004-10-01 2005-09-30 Promoting neochondrogenesis using kinase inhibitors TW200628158A (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US61548804P 2004-10-01 2004-10-01

Publications (1)

Publication Number Publication Date
TW200628158A true TW200628158A (en) 2006-08-16

Family

ID=35447209

Family Applications (1)

Application Number Title Priority Date Filing Date
TW094134143A TW200628158A (en) 2004-10-01 2005-09-30 Promoting neochondrogenesis using kinase inhibitors

Country Status (2)

Country Link
TW (1) TW200628158A (en)
WO (1) WO2006038112A1 (en)

Families Citing this family (36)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BRPI0620408B8 (en) 2005-12-21 2021-05-25 Novartis Ag pyrimidinyl aryl urea derivatives being FGF inhibitors, their uses, and pharmaceutical preparation
EP1882475A1 (en) * 2006-07-26 2008-01-30 Novartis AG Method of treating disorders mediated by the fibroblast growth factor receptor
EP3564240B1 (en) 2007-08-31 2022-04-06 Purdue Pharma L.P. Piperidine intermediates
WO2011065800A2 (en) * 2009-11-30 2011-06-03 주식회사 오스코텍 Pyrimidine derivative, method for preparing same and pharmaceutical composition containing same
US8754114B2 (en) 2010-12-22 2014-06-17 Incyte Corporation Substituted imidazopyridazines and benzimidazoles as inhibitors of FGFR3
CN107652289B (en) 2012-06-13 2020-07-21 因塞特控股公司 Substituted tricyclic compounds as FGFR inhibitors
US9388185B2 (en) 2012-08-10 2016-07-12 Incyte Holdings Corporation Substituted pyrrolo[2,3-b]pyrazines as FGFR inhibitors
US9266892B2 (en) 2012-12-19 2016-02-23 Incyte Holdings Corporation Fused pyrazoles as FGFR inhibitors
CN111793068A (en) 2013-03-15 2020-10-20 西建卡尔有限责任公司 Heteroaryl compounds and uses thereof
KR102350704B1 (en) 2013-03-15 2022-01-13 셀젠 카르 엘엘씨 Heteroaryl compounds and uses thereof
TWI647220B (en) 2013-03-15 2019-01-11 美商西建卡爾有限責任公司 Heteroaryl compound and its use
KR102269032B1 (en) 2013-04-19 2021-06-24 인사이트 홀딩스 코포레이션 Bicyclic heterocycles as fgfr inhibitors
KR101826015B1 (en) 2013-10-18 2018-02-06 에자이 알앤드디 매니지먼트 가부시키가이샤 Pyrimidine fgfr4 inhibitors
US10851105B2 (en) 2014-10-22 2020-12-01 Incyte Corporation Bicyclic heterocycles as FGFR4 inhibitors
CN104478742A (en) * 2014-11-24 2015-04-01 苏州乔纳森新材料科技有限公司 Fluoro compound and preparation method thereof
MA41551A (en) 2015-02-20 2017-12-26 Incyte Corp BICYCLIC HETEROCYCLES USED AS FGFR4 INHIBITORS
PE20171514A1 (en) 2015-02-20 2017-10-20 Incyte Corp BICYCLE HETEROCYCLES AS FGFR INHIBITORS
WO2016134294A1 (en) 2015-02-20 2016-08-25 Incyte Corporation Bicyclic heterocycles as fgfr4 inhibitors
CN107660200B (en) 2015-04-14 2022-01-11 卫材R&D管理有限公司 Crystalline FGFR4 inhibitor compounds and uses thereof
US11357769B2 (en) 2016-05-10 2022-06-14 Eisai R&D Management Co., Ltd. Drug combinations for reducing cell viability and/or cell proliferation
AR111960A1 (en) 2017-05-26 2019-09-04 Incyte Corp CRYSTALLINE FORMS OF A FGFR INHIBITOR AND PROCESSES FOR ITS PREPARATION
JOP20190282A1 (en) 2017-06-09 2019-12-05 Novartis Ag Compounds and compositions for inducing chondrogenesis
BR112020022373A2 (en) 2018-05-04 2021-02-02 Incyte Corporation salts of a fgfr inhibitor
SG11202010636VA (en) 2018-05-04 2020-11-27 Incyte Corp Solid forms of an fgfr inhibitor and processes for preparing the same
WO2020185532A1 (en) 2019-03-08 2020-09-17 Incyte Corporation Methods of treating cancer with an fgfr inhibitor
WO2021007269A1 (en) 2019-07-09 2021-01-14 Incyte Corporation Bicyclic heterocycles as fgfr inhibitors
WO2021067374A1 (en) 2019-10-01 2021-04-08 Incyte Corporation Bicyclic heterocycles as fgfr inhibitors
WO2021076602A1 (en) 2019-10-14 2021-04-22 Incyte Corporation Bicyclic heterocycles as fgfr inhibitors
WO2021076728A1 (en) 2019-10-16 2021-04-22 Incyte Corporation Bicyclic heterocycles as fgfr inhibitors
GB201915828D0 (en) * 2019-10-31 2019-12-18 Cancer Research Tech Ltd Compounds, compositions and therapeutic uses thereof
JP7720840B2 (en) 2019-12-04 2025-08-08 インサイト・コーポレイション Tricyclic heterocycles as FGFR inhibitors
CN115151539A (en) 2019-12-04 2022-10-04 因赛特公司 Derivatives of FGFR Inhibitors
WO2021146424A1 (en) 2020-01-15 2021-07-22 Incyte Corporation Bicyclic heterocycles as fgfr inhibitors
US12065494B2 (en) 2021-04-12 2024-08-20 Incyte Corporation Combination therapy comprising an FGFR inhibitor and a Nectin-4 targeting agent
AR126102A1 (en) 2021-06-09 2023-09-13 Incyte Corp TRICYCLIC HETEROCYCLES AS FGFR INHIBITORS
CA3220155A1 (en) 2021-06-09 2022-12-15 Incyte Corporation Tricyclic heterocycles as fgfr inhibitors

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2001029042A1 (en) * 1999-10-21 2001-04-26 F. Hoffmann-La Roche Ag Heteroalkylamino-substituted bicyclic nitrogen heterocycles as inhibitors of p38 protein kinase
JP2004519422A (en) * 2000-08-04 2004-07-02 ワーナー−ランバート・カンパニー、リミテッド、ライアビリティ、カンパニー 2- (4-Pyridyl) amino-6-dialkoxyphenylpyrido [2,3-d] pyrimidin-7-one
PA8577501A1 (en) * 2002-07-25 2004-02-07 Warner Lambert Co KINASE INHIBITORS

Also Published As

Publication number Publication date
WO2006038112A1 (en) 2006-04-13

Similar Documents

Publication Publication Date Title
TW200628158A (en) Promoting neochondrogenesis using kinase inhibitors
DK1836201T3 (en) Pyrrolidine Inhibitors of IAP
UA85593C2 (en) Quinazolinone derivatives as parp inhibitors
TW200745028A (en) Novel sulphonylpyrroles
PL372926A1 (en) Piperidine-pyridazones and phthalazones as pde4 inhibitors
DE60310576D1 (en) 2-hydroxy-6-phenylphenanthridine als pde-4-hemmer
MXPA06012595A (en) Amino-tetrazoles analogues and methods of use.
IL185275A0 (en) N-sulphonylpyrrole derivatives and pharmaceutical compositions containing the same
MY169515A (en) Quinazolinedione derivatives as parp inhibitors
GEP20094679B (en) Dipeptidyl peptidase inhibitors
MX2007003546A (en) Indozolone derivatives as 11b-hsd1 inhibitors.
GEP20084421B (en) Proline derivatives and their use as dipeptidyl peptidase iv inhibitors
MX2009004441A (en) Indazole derivatives useful as l-cpt1 inhibitors.
PT1940839E (en) Pyridopyrimidinone inhibitors of pi3kalpha
MX2008005398A (en) 4- (3-aminopyrazole) pyrimidine derivatives for use as tyrosine kinase inhibitors in the treatment of cancer.
ZA200701137B (en) Triazolophthalazines
ATE553093T1 (en) INDAZOLE DERIVATIVES FOR INHIBITING TRPV1 AND USES THEREOF
WO2005087724A3 (en) Sulphonylpyrroles as hdac inhibitors
TW200722421A (en) Azole derivatives as inhibitors of lipases and phospholipases
TW200745027A (en) Novel sulphonylpyrroles
MX2010007391A (en) Trpa1 antagonists.
MX2012006805A (en) Indolyl-piperidinyl benzylamines as beta-tryptase inhibitors.
MX2010001486A (en) Tetrahydropyridine carboxamide derivatives as trpvl antagonists.
EA201200891A1 (en) DERIVATIVES 3,4,4A, 10D-TETRAGIDRO-1H-TIOPIRANO [4,3-C] IZOHINOLINA
MX2011007165A (en) Pyridazinone derivatives.